Should you buy Bristol-Myers Squibb (BMY)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
BMY currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Consistent Earnings Beat Quality↑Improving
- Fully Priced Limited Room→Stable
- Dividend Payout And Leverage Strain↑Improving
- +1 more pillar — see the Why tab for full reasoning
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Beat Quality
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Fully Priced Limited Room
Trip ifPrice declines below $50.00, creating more than 13% upside to the current price target.
- P3Dividend Payout And Leverage Strain
Trip ifDividend payout ratio falls below 100% of earnings for 2 consecutive quarters.
- P4Momentum At Floor Falling Volume
Trip ifRSI rises above 60 and on-balance volume turns positive for 4 consecutive weeks.
How the engine reached this verdict
TrendMatrix's engine output for Bristol-Myers Squibb Company (BMY) is HOLD_IF_HOLDING with medium conviction, score 6.6/10 at $62.25. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF); Sector modifier (Healthcare): +0.5; Strong earnings beat streak (4/4). On the bear side: Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.0): -1.5. Active engine warnings: V8: Target reached (-3.6% upside), V9 Gate Failed: ASYMMETRY:-0.7=NEGATIVE.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $60.17 for existing positions. Asymmetric R:R is -0.71, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates BMY — 10-dimension breakdown →
Bull case
- ▸V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (4/4)
Bear case
- ▸Concentration risk — Geographic: United States (69.0%)
- ▸Analyst target reached - limited upside remaining
- ▸Leverage penalty (D/E 2.0): -1.5